NO20062594L - Transdermal delivery system of hormones without penetration enhancers - Google Patents

Transdermal delivery system of hormones without penetration enhancers

Info

Publication number
NO20062594L
NO20062594L NO20062594A NO20062594A NO20062594L NO 20062594 L NO20062594 L NO 20062594L NO 20062594 A NO20062594 A NO 20062594A NO 20062594 A NO20062594 A NO 20062594A NO 20062594 L NO20062594 L NO 20062594L
Authority
NO
Norway
Prior art keywords
hormones
patch
delivery system
transdermal delivery
penetration enhancers
Prior art date
Application number
NO20062594A
Other languages
English (en)
Other versions
NO341989B1 (no
Inventor
Michael Dittgen
Thomas Langguth
Dirk Schenk
Stefan Bracht
Petra Huber
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US52871803P priority Critical
Priority to EP03078881 priority
Priority to PCT/IB2004/052752 priority patent/WO2005058287A2/en
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20062594L publication Critical patent/NO20062594L/no
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34702342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20062594(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of NO341989B1 publication Critical patent/NO341989B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7076Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins

Abstract

Den foreliggende oppfinnelsen angår et plaster som omfatter et legemiddelinneholdende lag med lavt innhold av hormon, slik som gestoden, og eventuelt et østrogen (f.eks. etiny-lestradiol). Ved administrasjon av plasteret til en kvinne, oppnås plasmanivåer på minst 1,0 ng/ml av gestoden ved steady-state-betingelser uten behov for inkorporering av penetrasjonsenhancere eller permeasjonsenhancere i det legemiddelinneholdende laget. Tilfredsstillende plasmanivaer i hormonene oppnås også gjennom en periode på minst 1 uke, idet plasteret gjøres anvendelig til bruk ved svangerskapsforebygging hos kvinner med et prinsipp om administrasjon av plastrene én gang ukentlig.
NO20062594A 2003-12-12 2006-06-06 Transdermal administrasjon av hormoner uten behov for penetrasjonsenhancere. NO341989B1 (no)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US52871803P true 2003-12-12 2003-12-12
EP03078881 2003-12-12
PCT/IB2004/052752 WO2005058287A2 (en) 2003-12-12 2004-12-10 Transdermal delivery system of hormones without penetration enhancers

Publications (2)

Publication Number Publication Date
NO20062594L true NO20062594L (no) 2006-07-10
NO341989B1 NO341989B1 (no) 2018-03-12

Family

ID=34702342

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062594A NO341989B1 (no) 2003-12-12 2006-06-06 Transdermal administrasjon av hormoner uten behov for penetrasjonsenhancere.

Country Status (15)

Country Link
JP (1) JP4965263B2 (no)
KR (1) KR101168449B1 (no)
CN (1) CN1913878B (no)
AU (1) AU2004298930B2 (no)
BR (1) BRPI0417530B1 (no)
CA (1) CA2549916C (no)
CU (1) CU23868B1 (no)
EA (1) EA011160B1 (no)
EC (1) ECSP066694A (no)
IL (1) IL176112A (no)
MX (1) MXPA06006682A (no)
NO (1) NO341989B1 (no)
NZ (1) NZ548091A (no)
WO (1) WO2005058287A2 (no)
ZA (1) ZA200605713B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE502004000988D1 (de) 2003-02-21 2006-08-31 Schering Ag Uv-stabiles transdermales pflaster
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
DE102005050729A1 (de) * 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
FR2900048B1 (fr) * 2006-04-21 2012-11-16 Oreal Compositions comprenant un derive diphenyl-methane hydroxyle
AU2015203180B2 (en) * 2010-09-06 2016-06-30 Bayer Intellectual Property Gmbh Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)
ME02618B (me) 2010-09-06 2017-06-20 Bayer Ip Gmbh Transdermalni flasteri sa malom dozom i velikim oslobađanjem leka
DE102010040299A1 (de) * 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
NZ627242A (en) * 2012-01-27 2016-08-26 Agile Therapeutics Inc Transdermal hormone delivery

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0573133A1 (de) * 1988-10-27 1993-12-08 Schering Aktiengesellschaft Mittel zur transdermalen Applikation das Gestoden enthält
EP0555360A1 (en) * 1990-10-29 1993-08-18 Alza Corporation Transdermal contraceptive formulations, methods and devices
US5512292A (en) * 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
DE4329242A1 (de) * 1993-08-26 1995-03-02 Schering Ag Mittel zur transdermalen Applikation enthaltend Gestodenester
DE4405898A1 (de) 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
AU692944B2 (en) * 1994-11-18 1998-06-18 Hisamitsu Pharmaceutical Co., Inc. Percutaneously absorbable patch
JP4346696B2 (ja) * 1996-05-28 2009-10-21 久光製薬株式会社 経皮治療用装置
JP4167750B2 (ja) * 1997-04-16 2008-10-22 久光製薬株式会社 経皮吸収用基剤及び該基剤を含有する経皮吸収製剤
JP4399044B2 (ja) * 1998-10-14 2010-01-13 久光製薬株式会社 吸収促進剤及び該吸収促進剤を有してなる経皮吸収製剤
DE19906152B4 (de) * 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
EP1197212A4 (en) * 1999-07-01 2004-06-02 Hisamitsu Pharmaceutical Co Adhesive preparation for percutaneous absorption
DE10053375C1 (de) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen
US20020106402A1 (en) * 2000-12-05 2002-08-08 Hartwig Rod Lawson Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use

Also Published As

Publication number Publication date
BRPI0417530A (pt) 2007-03-13
ZA200605713B (en) 2008-01-08
CN1913878A (zh) 2007-02-14
IL176112D0 (en) 2006-10-05
BRPI0417530B1 (pt) 2018-01-23
CA2549916C (en) 2013-09-17
IL176112A (en) 2011-02-28
AU2004298930B2 (en) 2009-11-26
CU20100143A7 (es) 2011-10-31
WO2005058287A3 (en) 2006-03-02
JP2007513938A (ja) 2007-05-31
WO2005058287A2 (en) 2005-06-30
NO341989B1 (no) 2018-03-12
KR101168449B1 (ko) 2012-07-25
CA2549916A1 (en) 2005-06-30
KR20060128910A (ko) 2006-12-14
CN1913878B (zh) 2010-05-26
ECSP066694A (es) 2006-10-31
JP4965263B2 (ja) 2012-07-04
EA200601089A1 (ru) 2006-12-29
MXPA06006682A (es) 2006-08-11
NZ548091A (en) 2009-12-24
AU2004298930A1 (en) 2005-06-30
CU23868B1 (es) 2013-03-27
EA011160B1 (ru) 2009-02-27

Similar Documents

Publication Publication Date Title
Von Wittenau et al. The distribution of tetracyclines in tissues of dogs after repeated oral administration
ES2249763T5 (es) Sistema de administracion transdermica de farmaco potente de flujo bajo.
CN1137689C (zh) 提高甾体化合物稳定性的药物释放组合物
JP3534775B2 (ja) 17−デアセチルノルゲスチマートを単独でまたはエストロゲンと組み合わせて投与するための経皮パッチおよび方法
AU690578B2 (en) Skin patches and methods for providing testosterone
AU703064B2 (en) Means and method for hormonal contraception and/or acne treatment
CA1329126C (en) Compounds having anti-progestational and anti-estrogenic activities for induction of labor and for termination of pregnancy, as well as for the treatment of gynecological disorders
DE60127134T2 (de) Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel
EP0562041B1 (en) Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
KR100212961B1 (ko) 경피투여시스템
Abrams et al. Pharmacokinetic overview of Ortho Evra™/Evra™
RU2219926C2 (ru) Чрескожная терапевтическая система (чтс), содержащая антиоксидант
HIAI et al. Effect of escin on adrenocorticotropin and corticosterone levels in rat plasma
CA2183543C (en) Sexual steroid-containing transdermal therapeutic systems
JP2758908B2 (ja) 皮膚透過促進剤としてグリセロールモノオレエートを用いる治療系
IT1255258B (it) Composizioni farmaceutiche per l'applicazione per via nasale.
JP2003514875A (ja) 創傷治癒を改善し、薬を投与するためのプロペラント不要のスプレー式皮膚パッチ組成物
SA01210740A (ar) تركيب على شكل جرعات تؤخذ عن طريق الفم ممتدة الانطلاق.
BR0014282A (pt) Vacinas
US4383993A (en) Nasal dosage forms containing natural female sex hormones
US4315925A (en) Method of administering natural female sex hormones
NO20001410D0 (no) Liposomale bedøvelsesmidler med vedvarende frigjøring
AR098830A2 (es) Suspensiones acuosas estabilizadas para administración parenteral
NO952417L (no) Terapeutiske anvendelser og leveringssystemer for dehydroepiandrosteron
NO20002038L (no) Uløselige insulinsammensetninger

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE